Tempus AI

Notes

Tempus AI is a precision medicine company focused on using AI and genomics to advance cancer care and personalized treatment. Founded in 2015 by Eric Lefkofsky (Groupon founder) and headquartered in Chicago, Illinois, the company went public on NASDAQ in June 2024 under the ticker symbol TEM.

Tempus has built one of the world's largest clinical and molecular databases, combining genomic sequencing data with clinical outcomes to enable:

• Personalized cancer treatment recommendations
• Drug discovery and development support
• Clinical trial matching
• Real-world evidence generation

The company's AI platform analyzes this data to help physicians make more informed treatment decisions and to accelerate drug development.

Team

• Eric Lefkofsky - Founder & Chief Executive Officer
  • LinkedIn: linkedin.com/in/ericlefkofsky
  • Co-founder of Groupon

Additional Research Findings

• NASDAQ: TEM (publicly traded since June 2024)
• Founded by Eric Lefkofsky (Groupon founder)
• Seed investors: NEA, Revolution Growth
• Series G investors: Google Ventures (led), SoftBank ($200M, April 2024), Baillie Gifford, T. Rowe Price, Franklin Templeton
• SoftBank launched AI healthcare joint venture with Tempus in June 2024
• One of largest clinical and molecular databases in the world
• Chicago, Illinois headquarters
• Founded in 2015

Sources

• Tempus AI Official Website
• Tempus AI Investor Relations
• NASDAQ: TEM
• Tempus AI LinkedIn